everyone today Thank our and first you for joining morning you, and earnings call. good thank Jody for us quarter
our contributions saw at segment Health, commercialized continued year-over-year an generic from decisions delivering each quarter starting and in because those in posted nutritionals entities increase first the segments. our the driven of lower Performance government a Our and continue performance Pharmaceutical in well, sales foundation the has good owing margin steady XXXX strengths having start Chemicals Rising in new perform Chemicals performance provide and early future Human profit for to Europe. look prune Rising for sales, closer the and continued and Health and revenue regulatory and year, XX% in quarter industry Rising as our durable a laid Ingredients to Taking the given fiscal were of the return our sales by due to to and of and a in to loss Pharmaceutical us Performance to strong the reset from profitability the the mostly sales gross portfolio. our capabilities declines company, fiscal to in at while a of financial contributions Ingredients headwinds. segments to to reporting Human the sourcing business year-over-year with cash measures segments growth gross weather
talked and fiscal to gross about negatively profit which on last recoverable procedures a addition, volume next $X.X customers. portion the impacted And our average we quarter. and selling of In price in failure penalties to inventory also to with of overshadowed We supply by and customers erosion benefit disciplines we supply the increased the for the a million, supply levels. consecutive stock decreased ongoing maybe nice instituted quarter supply increase safety our with our were forward and quarter materialize. operational for Revenue third chain a claims began partners quarter, customer have our of projections to back orders. quarter Failure minimal those this represent from and improvements chain improve see the healthy
this chain worked has in year, control. Earlier the all I supply our we hard now team back Our highly were SKUs and of of the in XX% have areas confident fully am on order. extremely under
the of under back have with portfolio have SKUs. of orders. of X% to we our whittled We expect size, that our And do to since down level some
to However, unforeseen the a immediate what any of see I state in challenges progress barring have am we of more is benefit the to expect can future the product subsequent snapshot made proud in beyond quarters. much present which bottom top today. an line holistic and show we our
portfolio. product Rising the to Turning
market our strong well differentiated selections optimize focusing opportunities. our pipeline return candidates, high efforts to continued We development on and product
As fiscal made the and XXXX, strategic pipeline conditions product technical challenges. development of in and XX to rationalize products unfavorable number a down cut this market reminder, our to during we decision due to
added additional based our age bringing to we XX-month we approved We to products These in four on and XX have fiscal call, ANDAs technical from age to are filed these products queue resolved. from which during ANDAs two and API since other pipeline file added plan two. to personally and favorable also received the FDA. We quarter which and we molecules challenges on molecules reported filed our to launch to our feedback greater recently molecules. were XX in a than launch greater ANDAs XX-month for we we the parked XX two in feedback quarter due added five those product X the category. have pipeline and file, once to due file, plan an We products, our were launch parked total have on than two one development FDA. these issues pipeline Previously, the our our pending molecules and Since restart one products a XX approved last category back We in We current launch. category. launched ANDA when
heard examples and are off bring previously products additional might ability back You this products to discussed back X future. bring of the good discuss the I environment them just shelf. the to for and me parked products the The we monitor continue we in
some For technical in XX plan commercialized partners we fiscal products complexity. XX to portfolio launch still are XXXX, terms diversified of there assuming and manufacturing generic more to
milestone million We also still R&D plan payments this fiscal in spend under $X year. just for to
profit in sales, API a reflecting strong X.X% increase increase to a favorable launch. Turning from sold lift on a abroad saw generated Pharmaceutical mix. XX.X% customer Ingredients, gross a we an and new in demand
because one with an of in that U.S., existing Here decreased fiscal of excess increased quarter inventory, which we two. the our created in sales competition off will customer sell
a ingredients agricultural a import Chemicals into our DEA related to issues products compared protection reclassification our issue, to In ran issuance. last year, in reflecting notification normal addition, Specialty in generated regulatory sales on flat gross alert business. of segment, profit In a and three compliance product Performance results gain our our were an Class X the colleagues a India X.X% In teams business, and Protection discussed with industry, a the positive takes increase competitor’s is puts our Chemicals X.X% and another used intelligence a business. have sourcing one competitive that great demand, results drove this advantage China’s from what in China in resulting customer increase shortage. with fuel an Campaign by supply I is primarily the in Blue we market yet previously and from quarter’s product example new a award for driven Sky believe revenue and this
We on plans. the effect September. board that our with our to successfully XX% plans And implemented are our business most in protect to-date, have customers of concerning went tariffs into
to the details higher exposure. the allows them will dependable margin, take on consistent I could in are Performance relationship and aware on by summary, that To administration of have fact imports that demonstrate with Becky last and CFO, product customer products the are quarter’s the in tariffs financial for impact customers results X, will on first we this call and Pharmaceutical to with analysis. the our call, will conducted on our our to analysis focus the over As provide I increase continued Rebecca portfolio XX% development customers. on us XX% to rigorous January through value. volume give likely Roof, to be to you prepared for turn that, the of review a Becky? an increase of lower quarter. enacted mentioned In Chemicals maximize possibility Chinese if we detailed has Ingredients value tariffs And some to more